NCT04864353

Brief Summary

Background: Cognitive impairment and difficulties are frequently observed in individuals suffering from major depressive disorder. These impairments and difficulties can persist into remission as residual cognitive symptoms. Consequently affecting daily life functioning and quality of life for those affected. Few scalable interventions have targeted these symptoms and measured long-term clinical effects such as depression relapse.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 21, 2021

Completed
5 days until next milestone

Study Start

First participant enrolled

April 26, 2021

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 28, 2021

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2023

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2024

Completed
Last Updated

March 12, 2025

Status Verified

March 1, 2025

Enrollment Period

2.5 years

First QC Date

April 21, 2021

Last Update Submit

March 10, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Behaviour Rating Inventory Of Executive Function-Adult

    The Behavior Rating Inventory of Executive Function-Adult (BRIEF-A; Roth, Isquith, \& Gioia, 2005) is a 75-item self-report questionnaire designed to measure adults' behaviors associated with executive problems.

    2.5 years

  • Perceived Deficit Questionnaire 5

    Brief assessment of subjective cognitive difficulties and covers problems with concentration (e.g. "trouble concentrating on things like watching a television program or reading a book?"), memory (e.g. "forget what you talked about after a telephone conversation?"), and executive functioning (e.g. "have trouble getting things organized?"). Every item is rated on a scale of 0 (Never) to 4 (Almost always) to yield a sum score of 0 to 20, with higher scores indicating greater severity of cognitive symptoms.

    2.5 years

Secondary Outcomes (8)

  • Rumination Response Scale

    2.5 years

  • Montgomery Aasberg Depression Rating Scale

    2.5 years

  • Patient Health Questionaire 9 and 2

    2.5 years

  • The Satisfaction With Life Scale

    2.5 years

  • The Credibility/Expectancy Questionnaire

    8 months

  • +3 more secondary outcomes

Study Arms (2)

Experimental: Intervention

EXPERIMENTAL

Participants will after baseline receive a guided intervention with weekly therapist support.

Behavioral: RestDep: Internet-delivered intervention targeting residual cognitive symptoms

Control: Waitlist

NO INTERVENTION

Participants will not receive intervention until 7 weeks after baseline.

Interventions

The intervention is fully digital with weekly telephone guidance. Key intervention elements are 1) psychoeducation, 2) attention training, 3) strategy training. Cognitive domains as attention, memory and executive functions are covered and rumination.

Experimental: Intervention

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Previously received treatment for major depressive disorder in primary or secondary healthcare services
  • Reporting a history of major depressive disorder symptoms assess using the MINI. few or minor depression symptomss (\< 12 MADRS)
  • Not meeting criteria for major depressive disorder measured by the MINI)
  • Self-reporting residual cognitive symptoms that affects daily functioning (assessed by clinical psychologist)
  • No changes in anti-depressant medication under the study period
  • Age between 18 and 65 years
  • Read and write Norwegian
  • Internet and telephone access.

You may not qualify if:

  • Self-reported substance abuse
  • Neurological conditions or damage (e.g. autism, cerebral haemorrhage, and brain tumour)
  • Bipolar disorder
  • Psychosis.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Haukeland University Hospital

Bergen, Norway

Location

Related Publications (1)

  • Myklebost SB, Heltne A, Hammar A, Nordgreen T. Efficacy of an internet-delivered cognitive enhancement intervention for subjective residual cognitive deficits in remitted major depressive disorder: A randomized crossover trial. J Affect Disord. 2024 Nov 1;364:87-95. doi: 10.1016/j.jad.2024.08.035. Epub 2024 Aug 12.

MeSH Terms

Conditions

Cognitive Dysfunction

Condition Hierarchy (Ancestors)

Cognition DisordersNeurocognitive DisordersMental Disorders

Study Officials

  • Tine Nordgreen, PhD

    Projectleader

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
The assessor do not allocate the participant to the intervention or waitlist group.
Purpose
TREATMENT
Intervention Model
SEQUENTIAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 21, 2021

First Posted

April 28, 2021

Study Start

April 26, 2021

Primary Completion

October 31, 2023

Study Completion

April 30, 2024

Last Updated

March 12, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations